Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Silica is a proven and highly effective anti-caking agent that has been used for decades
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
We now rank 3rd in pharmaceutical production by volume and 14th by value
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Subscribe To Our Newsletter & Stay Updated
